Plan Outlines Incentives for New Vaccines

MAY 01, 2005

Experts agree that a plan to provide market incentives for pharmaceutical and biotech companies to develop vaccines against diseases that kill millions of individuals in developing countries annually can significantly advance global health. The Center for Global Development (CGD) working group released its report, Making Markets for Vaccines: Ideas to Action, on World Health Day, April 7, 2005. The plan calls for rich countries and other donors to pledge to buy new vaccines for diseases such as malaria and HIV/AIDS, strengthening the incentive for companies to invest in research and development.

The report states that a market of $3 billion is required to provide incentives for companies to develop a new medicine. For instance, sponsors could pledge to underwrite a price of $15 per treatment for a malaria vaccine for the first 200 million treatments. At this price, the advance market commitment would be a bargain, compared with many other development costs. This plan also could speed delivery of recently developed vaccines.

"This approach unleashes the same market incentives that have been so effective in improving the health of people in rich countries," said Nancy Birdsall, president of CGD. "And it ensures that, once a vaccine is developed, the funds will be there to get the vaccine to the people who need it."



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.